本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI, Oct. 17, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd is pleased to announce in October 2023, we have obtained ISO 9001 and IPMS certifications. These certifications emphasize Sanyou's commitment to consistency, reliability, and accountability in our innovative biopharmaceutical drug R&D and technical services in the field of biomedical science and technology. ISO9001:2015 is a globally recognized international quality management system standards and IPMS certification represents the highest level of accreditation for intellectual property management system in China. Sanyou is committed to bridging the gap between drug R&D and the entire life-cycle manufacturing supply chain. We have established the 4C business model that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS". Our proprietary platform and technology undergo continuous optimization, with periodic upgrades and new version of services and technologies, all aimed at becoming the most trusted partner in the hearts of our customers. About Sanyou Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biological drugs. We received National-level certification as a high-tech enterprise, are recognized as a Specialized and Sophisticated enterprise by the Shanghai Municipal Government, are part of the "Zhangjiang Star" incubation program in Shanghai, have been certified as an innovative small and medium-sized enterprise，and passed the ISO9001 quality assurance certification. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS", to accomplish the mission "to make it easy to discover innovative biological drugs anywhere". Since its establishment 8 years ago, Sanyou has maintained rapid growth. As of september 2023, the company has a professional team of nearly 300 employees, and most of them have a Ph.D. or master degree. Sanyou's team possesses rich experience in innovative drug development and industrialization. Sanyou has established an integrated innovative biological drug R&D laboratory of twenty thousand square meters with advanced facilities in Shanghai Caohejing Hi-Tech Park. Sanyou has built three industry-leading innovative technology platforms featured by "super-trillion, integration, and intelligence" , and has built more than 50 sub-platforms with the core innovative technologies represented by super-trillion phage display platform, and supported by platforms of material preparation, antibody discovery, molecule optimization, in vitro and in vivo efficacy, production cell line construction, upstream and downstream process development, preclinical R&D, industrialization development, etc. Sanyou's proprietary platform and technology are in continuous optimisation，we launch from time to time upgrades and new version of services and technologies based on principles of innovation, outstanding and reliability. Our business network has expanded to all parts of the world, including China, US and Europe, and established branches in Boston, San Diego, Philadelphia, Rotterdam and London. Our company has established friendly business collaboration with more than 1000 pharmaceutical companies, drug R&D institutions and diagnostics companies worldwide. Excellence and innovation, pursuit of dreams, striving and evolving, for the benefit of patients. Sanyou looks forward to jointly building a long-term collaborative growth ecosystem and a healthy community with our clients and partners. You can visit us more: https://www.sanyoubio.com
SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, today announced its SAFETYscan®47 platform as a New Approach Methodology (NAM), part of a standardized framework aiming to revolutionize chemical risk assessments. The established platform provides in vitro high-throughput screening within this NAM framework, empowering researchers in diverse sectors with faster and cost-effective tools to assess chemical-related risk to human health. The SAFETYscan47 functional panel comprises 47 human-relevant targets pivotal in the assessment of clinical adverse drug reactions (ADRs), supporting all pharmaceutical drug discovery stages and aligning early safety evaluations with clinical predictions, in addition to supporting other research domains such as food, cosmetics, and industrial chemicals. A recent case study published in the Society of Toxicology showcases its utility with in vitro risk assessment. This SAFETYscan47 recognition offers solutions to challenges posed by traditional in vivo risk assessments. Beyond ethical concerns, they fail to fully replicate human in vivo mechanistic-related adverse events. Human genetic diversity is rarely considered, leading to uncertainties in translating results to human populations. Eurofins Discovery's platform addresses these issues by delivering human-relevant, functional data with higher throughput and at lower costs. Developed in alignment with the European Commission's chemicals strategy, U.S. EPA's Chemical Safety for Sustainability Strategic Research Action Plan, and other global strategies, SAFETYscan47 echoes the international drive for chemical-risk mitigation. By integrating in vitro to in vivo extrapolation (QIVIVE) and leveraging mechanism-based methods, this Eurofins Discovery technology supports global efforts to ensure a toxic-free environment and safe therapeutic development. With its focus on efficiency and accuracy, SAFETYscan47 is a breakthrough in modern chemical safety evaluation. About Eurofins Discovery Eurofins Discovery is recognized as the industry leader for providing drug discovery researchers with the largest and most diverse portfolio of standard and custom in vitro safety & pharmacology assays and panels for drug screening and profiling. In addition to in vitro safety pharmacology strengths, Eurofins Discovery also offers a broad portfolio of over 3,500 drug discovery services and 1,800 products. These include in vitro assays, cell-based phenotypic assays, safety pharmacology and efficacy, ADME toxicology, medicinal chemistry design, synthetic chemistry, and custom proteins and assay development capabilities. Eurofins Discovery supports a variety of drug discovery targets such as GPCRs, Kinases, Ion Channels, Nuclear Hormone Receptors and other proteins and enzymes. Eurofins Discovery's capabilities, expertise, knowledge and skill sets allow clients to work with a single outsourcing provider (CRO) for all their drug discovery programs. Eurofins Discovery is part of the international network of Eurofins laboratories. About Eurofins – the global leader in bio-analysisEurofins is Testing for Life. With over 62,000 staff across a network of ca. 900 laboratories in 61 countries, Eurofins offers a portfolio of over 200,000 analytical methods. Eurofins Shares are listed on Euronext Paris Stock Exchange.
SUNWAY CITY, Malaysia, Oct. 2, 2023 /PRNewswire/ -- Sunway Lagoon proudly announced the 9th annual multi-award and iconic Nights of Fright (NOF9) event in partnership with The Sudden Impact! Entertainment Company from New York. Running from September 29th to October 31st, 2023, every Friday, Saturday, and Sunday, from 7.30 pm to 11.30 pm, this year's event promises to raise the bar for Halloween experiences in Kuala Lumpur with its brand-new horror theme, "Fields of Fear." Launched back in 2013, Nights Of Fright: Festival Of Fear had established itself as Malaysia's one-stop destination for thrill-seekers and horrorphiles to gather every Halloween season. With the most haunted attractions in Asia, NOF9 raises the bar every year with different themes and concepts where adventurers who thirst for a scream-filled night are in for a trick-or-treat during selected nights of the October Halloween season! This year, Nights Of Fright 9 have every intention to create the most immersive Halloween experience by transporting all who walked their haunted lands into a nightmarish world where irrational fears are intensified and the line between reality and nightmare is blurred. With cutting-edge special effects, intricate set designs, and professional scare actors, NOF9 promises an alternate purgatory experience. Eight themed haunted houses, 11 thrilling rides, two scare zones, two show stages, and the new and larger Scarytales Theatre await guests. Four terrifying highlights include: TEXAS CHAINSAW MASSACRE - OUT.BACK. ATTACK! An iconic horror classic exploring Leatherface's lair, filled with scalps and victims. Not for the faint of heart. ANIMALIUM After the Harvest, a toxic wasteland emerges with humans transformed into 'humanimals.' Strange characters make this wasteland their new home. THE LEGEND OF SWEENEY TODD: BARBERSHOP KILLER OF FLEET STREET Enter Sweeney Todd's infamous barber shop and face Mrs. Lovett's meat pies. Can you stomach the truth behind these devilish delicacies? MURDER AT MADAME ZHU'S Experience Chinatown chaos at Madame Zhu's Noodle House in Hong Kong. A crazy chef is on the loose, butchering customers in horrific scenes. "As otherworldly horror might fade once you escape our Gates of Hell, but the terror that hits close to home lingers like an unbreakable curse. That's why we've delved into local and Asian heritages to unearth terrifying stories that will plant a seed of fear even in the hearts of our bravest visitors." said Ms. Michelle Soong, Sunway Theme Parks' Assistant General Manager - Marketing & Park Experiences. Public favorites from past years such HAMMER-ICONS OF HORROR and THE ASYLUM are also making a comeback in their line-up of spine-tingling horror nights. The infamous haunted Lost City Of Gold Scream Coaster, Apache Pots and other thrilling rides will also be available during the horrorfest. With new, alluring shows and performances such as THE REVENGE OF LITTLE RED and ZOMBIE ENCOUNTER beguiling the night, the finale party, FREAKY NIGHTMARES with bewitching and intoxicating tunes will mark the end of the horror every night. Sunway Lagoon & The Sudden Impact! Entertainment Company has spared no effort to bring forth the best and most fearsome experience with our official partners - SAYS, MAC, Vivo, AirAsia Ride, F&N, Astro Radio (MY, Hitz, Sinar, Mix, Lite, Gegar, Goxuan, Syok), Sunway Pyramid Ice, Petron and Tourism Selangor. Sunway Lagoon invites all thrill-seekers to join them for an unforgettable journey into the depths of fear and excitement during the 9th year of Nights of Fright: Festival Of Fear. Get ready to scream, laugh, and create haunting memories!
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints.- 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment.- Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in the treated area after CBL-514 treatment.- 42.9% of participants lost at least 150mL of subcutaneous fat in the treated area after only one CBL-514 treatment. TAIPEI, Oct. 2, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced the topline results of the CBL-0202 stage 2 phase 2 study met all the primary and secondary efficacy endpoints compared with placebo in the ITT (Intent-to-treat) and PP (per-protocol) analysis population. "According to the study published in the Aesthetic Surgery Journal in 2012, liposuction could remove a mean of the subcutaneous fat volume of 183.3mL," said Vivian Ling, CEO of Caliway, "We are delighted to see that CBL-514 demonstrated the efficacy on subcutaneous fat reduction more effective than liposuction in the CBL-0202 stage 2 phase 2 study, reducing over 300mL of subcutaneous fat averagely." Topline Results from the CBL-0202 Phase 2-stage 2 Study Primary Endpoint 63.9% and 69.6% of participants in the CBL-514 group who lost at least 150 mL of subcutaneous fat in the treated area at 4 weeks and 8 weeks after treatment; while in the placebo group, 17.4% and 0.0% of participants who lost at least 150 mL of subcutaneous fat in the treated area at 4 weeks and 8 weeks after treatment. The percentage of participants who lost at least 150 mL of subcutaneous fat in the treated area at 4 weeks (p<0.001) and 8 weeks (p<0.00001) after CBL-514 treatment was significantly higher than the placebo group and achieved the primary endpoint. Secondary Endpoints 58.3% and 60.9% of participants in the CBL-514 group who lost at least 200 mL of subcutaneous fat in the treated area at 4 weeks and 8 weeks after treatment; while in the placebo group, 8.7% and 0.0% of participants who lost at least 200 mL of subcutaneous fat in the treated area at 4 weeks and 8 weeks after treatment. The percentage of participants who lost at least 200 mL of subcutaneous fat in the treated area at 4 weeks (p< 0.0002) and 8 weeks (p< 0.0001) after CBL-514 treatment was significantly higher than the placebo group. Compared with the placebo group, the LS mean (least square mean) difference of the subcutaneous fat volume change in the treated area at 4 weeks and 8 weeks after CBL-514 treatment were -312.08 mL (p<0.00001) and -276.83 mL (p<0.00005). 42.9% of participants lost at least 150 mL of subcutaneous fat in the treated area after one CBL-514 treatment. Overall, the safety and tolerability profiles of CBL-514 demonstrated in the study were favorable and consistent with previous clinical studies of CBL-514. Major TEAEs were ISRs (injection site reactions) that were mild and moderate, and most TEAEs were resolved before the end of the study visit. About the CBL-0202 Stage 2 Study The CBL-0202 stage 2 study (NCT04897412) is a randomized, single-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, and tolerability of CBL- 514 injection for abdominal subcutaneous fat reduction approved by the U.S. Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA). CBL-514 will be administered via injection into the subcutaneous adipose layer on the abdomen. The trial randomized 76 participants across the U.S. and Australia in a 2:1 ratio to receive CBL-514 or a placebo. Each participant will receive up to 4 treatments of allocated CBL-514 or placebo administered on the abdomen once every 4 weeks and complete the two follow-up visits after the last treatment. The maximum dose is 600 mg per treatment, depending on the level of subcutaneous fat accumulation on the participant's abdomen. The primary efficacy endpoint of the CBL-0202 -stage 2 phase 2 study is the percentage of participants who lost at least 150 mL of abdominal subcutaneous fat as measured by ultrasound at 4 weeks and 8 weeks follow-up visits after treatment compared with placebo. The critical secondary efficacy endpoints include the percentage of participants who lost at least 200 mL of abdominal subcutaneous fat as measured by ultrasound at 4 weeks and 8 weeks follow-up visits after treatment compared with placebo, and reduction of subcutaneous fat volume over the treated area as measured by ultrasound from Baseline to follow-up visits compared with placebo. About Fat Reduction The current methods for fat reduction include non-invasive products and invasive surgery, such as liposuction and abdominal contour surgery. The efficacies of non-invasive products often take more than twelve weeks to show, and are generally poor with the limited treatment body area. The potential moderate to severe side effects of non-invasive products include tissue necrosis, nerve damage, scar tissue fibrosis, and paradoxical adipose hyperplasia (PAH). Though the efficacy of surgery is more significant compared to approved non-surgery local fat reduction products, the surgery still comes with severe side effects and a high risk of death. According to the American Society of Plastic Surgeons' report, more than 60% of people are reluctant to undergo local fat reduction due to the fear of the side effects. The medical needs for local fat reduction remain unmet. About CBL-514 CBL-514, a first-in-class small-molecule drug, is an injection lipolysis drug that can induce adipocytes apoptosis and lipolysis to reduce subcutaneous adiposity in treatment areas in animal studies without causing any systematic side effects on the central nervous system, cardiovascular system, and respiratory system. Caliway's nonclinical studies showed that CBL-514 inhibits the cell survival kinase DYRK1b, upregulates the apoptosis mediators caspase 3 and Bax/Bcl-2 ratio, and then induces dose-dependent adipocyte apoptosis in vivo and in vitro. Caliway is investigating multiple indications for CBL-514, including non-invasive fat reduction (reducing subcutaneous fat), Dercum's disease, cellulite, and lipoma treatment. About Caliway Biopharmaceuticals Caliway Biopharmaceuticals (Caliway), is a Taiwan-based, clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics to help patients suffering from illness or life-threatening diseases. In Caliway, we aim to become an innovative pharmaceutical leader in medical aesthetics and inflammatory disease. For more information, please visit: www.Caliway.com.tw/en
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present five programs at the 2023 Society of Immunology in Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023. As the world's largest and most anticipated gathering in the field of immuno-oncology, the SITC Annual Meeting is designed to promote scientific exchanges and cooperation for improving treatment outcomes for cancer patients. The presentations feature five Antengene's clinical and preclinical programs, including two clinical programs, the anti-CD24 monoclonal antibody ATG-031 and the PD-L1/4-1BB bispecific antibody ATG-101; two preclinical programs, the LILRB4 antagonist antibody ATG-034 and the GPRC5D/CD3 T-cell engager ATG-021; as well as the proprietary novel AnTenGager™ platform. Details of those poster presentationsATG-031(anti-CD24 monoclonal antibody)Title: The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignanciesAbstract: 1337Date: November 3, 2023Time: 9:00 AM - 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023 ATG-101(PD-L1/4-1BB bispecific antibody)Title: Single-cell RNA sequencing reveals the positive feedback activation loop between T and dendritic cells induced by PD-L1x4-1BB bispecific antibodyAbstract: 1112Date: November 4, 2023Time: 9:00 AM - 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023 ATG-034 (LILRB4 antagonist antibody)Title: Antibody targeting a specific epitope of LILRB4 induces potent ADCC/ADCP effect against leukemia cellsAbstract: 1391Date: November 3, 2023Time: 9:00 AM - 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023 ATG-021 (GPRC5D/CD3 T-cell engager)Title: ATG-021, a novel 2+1 CD3-based T-cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine releaseAbstract: 1191Date: November 3, 2023Time: 9:00 AM - 7:00 PM Pacific Time; 0:00 AM – 10:00 AM Beijing Time, November 4, 2023 AnTenGager™ PlatformTitle: A novel "2+1" bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRSAbstract: 1190Date: November 4, 2023Time: 9:00 AM - 8:30 PM Pacific Time; 0:00 AM – 11:30 AM Beijing Time, November 5, 2023 About AntengeneAntengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, South Korea, Singapore and Australia. Forward-looking statementsThe forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2022, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact: Investor Contacts: Donald LungE-mail: Donald.Lung@antengene.com Mobile: +86 18420672158 PR Contacts:Peter QianE-mail: Peter.Qian@antengene.com Mobile: +86 13062747000
根據市調機構最新調查結果，2023年8月台灣實體通路智慧手機市場銷售量僅賣出34.4萬台，與7月的37.3萬台相比減少2.8萬台，銷售額也較上月稍跌9%，買氣不漲反跌；進一步觀察手機品牌銷售佔比排名，傑昇通信表示，本月市占排名由三星以33.2%的市占率，大贏蘋果8個百分點拿下第一，蘋果則因果粉觀望新機與iPhone 14旗艦機型庫存水位觸底，市占率下滑至25.2%退居第二，OPPO則是14.1%，vivo及紅米市占分別為8.5%與6.9%。 三星稱霸！奪下8月手機市占冠軍 全台最大連鎖通訊門市─傑昇通信觀察8月各品牌前三名的熱銷機型，本月市占銷售第一的三星，8月市佔率33.2%，與上月29.8%相比，多出3.4個百分點，成為本月手機銷量第一品牌，雖然iPhone新機上市前影響果粉出手，但主要還是三星Galaxy A系列機型銷量長紅，折疊新機Z Flip 5逆風上揚，剛上市的單機銷售數量就與iPhone 14 Pro Max（256GB）相差百台、以及S23 Ultra旗艦進入長銷模式，銷量因而超越蘋果；不過本月三星銷售較佳的前三名機型，都是目前通路售價在萬元左右的中低階A系列手機，在銷售額的部分就無法與蘋果匹敵。 本月適逢iPhone新機發表前果粉呈現觀望狀態，品牌銷量短暫銷售下滑至25.2%屈居第二，且較7月衰退23%，也是五大品牌衰退最多，換算iPhone在8月的銷售量比7月再少2.6萬台，就連品牌前三名熱銷的iPhone單機銷量也全數下降，且以第三名的iPhone 14 Pro Max（256GB）單機銷量更大跌34%；傑昇通信表示，顯見iPhone新機上市前，舊旗艦便很難買到，至於蘋果在銷售額雖較7月下滑，仍保有42.2%的占比居冠，幾乎吃下台灣手機市場半壁江山。 除了蘋果與三星之外，傑昇通信指出，這次市占14.1%的OPPO再傳捷報，同樣受惠新機帶動，品牌銷售量成長12%，銷售額也大增33%，成為本月銷售表現最佳的品牌；尤其剛上市的新機OPPO Reno10 Pro無懼手機市場買氣低落，不僅進入全台熱銷榜，也是品牌熱賣第一名的單機，成績亮眼，第二、三名的5G手機A78，主打5千大電量33W閃充使用體驗，具有IPX4日常生活防水等級，外型好、各項功能都有不錯的水準，免七千的入手價，人氣依然居高不下。 vivo Y27一鳴驚人 助力品牌銷售額 本月市占率8.5%的vivo，整體銷售額較上月成長9%超車紅米，主要是7月才上市的實力派新機Y27，8月便成為品牌銷售冠軍，第二名的Y16上市一年，已進入產品銷售周期末端，本月透過與系統業者專案促銷，意外催出較上月成長62%的銷量；敬陪末座的紅米市占6.9%，品牌銷量與銷售額皆下跌逾1成，前三名機型與上月同；傑昇通信分析，本月手機市場同質性機型多，規格齊備的5G手機價格也不貴時，CP值優勢不再，中階新機對消費者來說更有吸引力。
A12 藝術空間
vivo
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
